Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display

53P - Radiotherapy utilization rate for breast cancer in Indonesia: A call for empowering cancer care

Date

02 Dec 2023

Session

Poster Display

Presenters

Donald Manuain

Citation

Annals of Oncology (2023) 34 (suppl_4): S1480-S1484. 10.1016/annonc/annonc1375

Authors

D.A. Manuain1, G.B. Prajogi2, T.B.M. Permata2, H. Handoko3, S.M. Sekarutami2, S. Gondhowiardjo2

Author affiliations

  • 1 Radiation Oncology, Universitas Indonesia, 10430 - Central Jakarta/ID
  • 2 Radiation Oncology, RSUPN Dr. Cipto Mangunkusumo, 10430 - Central Jakarta/ID
  • 3 Radiotherapy Department, University of Indonesia - Faculty of Medicine, 10430 - Central Jakarta/ID

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 53P

Background

Breast cancer is the predominant malignancy in Indonesia, as per recent data from The Global Cancer Observatory (GLOBOCAN) 2020. Employing a multifaceted therapeutic approach has curbed breast cancer patient mortality. Radiotherapy's pivotal role in comprehensive breast cancer care underscores its significance. This study marks the inaugural effort to assess radiotherapy utilization rate (RUR) among Indonesian breast cancer patients.

Methods

Secondary data were gathered from breast cancer patients diagnosed within Indonesian radiotherapy centers during 2019-2021. The primary goal was a pre-pandemic evaluation of radiotherapy utilization. After rigorous data cleansing, involving duplicate elimination, meticulous analysis ensued. This unveiled actual RUR (aRUR) and optimal RUR (oRUR) for this cohort. Comparative RUR assessment with global counterparts complemented the analysis.

Results

This study encompassed 11,037 breast cancer patients from 34 Indonesian radiotherapy centers. Of these, 96.8% were female, with a minority (2.6%) being male. Notably, 60.38% were diagnosed at advanced stages (Stages 3 and 4), mirroring developing nation trends. 17 radiotherapy centers met the criteria for aRUR analysis, resulting in 26.2%. For oRUR, 9 centers were suitable, indicating 66.3% (50.7% - 78.2%). Consequently, unmet RUR needs in Indonesian breast cancer patients stood at 60.4% (48.3% - 66.4%). Data from Australia's Cancer Collaboration for Cancer Outcomes, Research & Evaluation (CCORE) 2013 exhibited a higher oRUR of 83.5% (82.5% - 84.6%), attributed to significant stage distribution differences.

Conclusions

The underutilization of radiotherapy for Indonesian breast cancer patients persists. A notable disparity between oRUR and aRUR remains. Given these outcomes, imperative next steps entail delving into underlying factors fueling this gap and devising targeted strategies to mitigate the concern.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.